Recursion Pharmaceuticals, commonly referred to as Recursion, is a pioneering biotechnology company headquartered in the United States. Founded in 2013, Recursion has rapidly established itself at the forefront of drug discovery and development, leveraging advanced machine learning and high-throughput biology to transform the way diseases are treated. With a strong operational presence in major regions across the US, Recursion focuses on utilising its unique platform to identify novel therapeutics for a range of conditions, particularly in rare diseases and oncology. The company’s innovative approach combines vast biological data with cutting-edge technology, setting it apart in the competitive biotech landscape. Notable achievements include significant partnerships and collaborations that enhance its market position, underscoring Recursion's commitment to revolutionising healthcare through data-driven insights and transformative therapies.
How does Recursion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Recursion's score of 24 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Recursion Pharmaceuticals, Inc. reported total carbon emissions of approximately 1,249,580 kg CO2e, comprising 269,260 kg CO2e from Scope 1 and 980,320 kg CO2e from Scope 2. The company has not disclosed any emissions data for 2023, nor does it have reported Scope 3 emissions. Recursion has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from a parent organization, indicating that it operates independently in its climate reporting. Overall, while Recursion has made strides in disclosing its emissions, it currently lacks defined climate commitments or reduction strategies, placing it in a context where further action may be necessary to align with industry standards for sustainability and climate responsibility.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 269,260 |
| Scope 2 | 980,320 |
| Scope 3 | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Recursion has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
